ODTx Management
(John Santini, Cynthia Stevenson, and
Jonathan Coppeta)
John T. Santini, Jr., PhD -- President & CEO
Dr. John Santini is a life science executive, entrepreneur, and
scientist that has spent his career focused on the creation and
growth of businesses developing advanced drug delivery and
biosensor products. As President & CEO of On Demand
Therapeutics, Inc. (ODTx), Dr. Santini is leading the development
of a physician controlled drug therapy product for the treatment of
retinal diseases such as wet age-related macular degeneration.
Prior to ODTx, he led the development of wireless, implantable drug
delivery and biosensor devices as President & CEO of
MicroCHIPS, Inc. Dr. Santini is a recognized expert in the
application of microtechnology in healthcare and has over 100
patents and patent applications. He has been honored as one of
Popular Science Magazine's "Brilliant Ten" and one of the Top 100
Young Innovators in the world by Technology Review Magazine, and
his work resulted in a Technology Pioneer award from the World
Economic Forum (Davos, Switzerland) and a Gold Medal from the
Edison Awards in the Science and Medical, Game Changers category.
Dr. Santini obtained his PhD in chemical engineering from MIT as a
National Science Foundation Fellow and his BSE in chemical
engineering from the University of Michigan.
Cynthia L. Stevenson, PhD -- Vice President,
Pharmaceutics
Dr. Cynthia Stevenson is Vice President of Pharmaceutics at On
Demand Therapeutics. Dr. Stevenson brings 20 years of experience in
drug development spanning a variety of therapeutic areas and drug
delivery platforms. Previously, she developed peptidomimetics as
Senior Director of Product Development at Ethos. Dr. Stevenson was
Director of Drug Development at Nektar Therapeutics, where she
played multiple roles in the development of insulin for pulmonary
delivery (Exubera®). She was Associate Director of
Formulation Development at Alza Corporation (now J&J), where
she was a co-inventor of novel formulations for the Duros implant
and provided leadership for the approval of the leuprolide implant
(Viadur®). Dr. Stevenson's leadership has resulted in
two successful NDA approvals and the entry of seven drug candidates
into clinical trials. She has also held scientific positions at
Glaxo Research Institute and The Upjohn Company (now Pfizer). She
received her MS and PhD degrees in Pharmaceutical Chemistry at The
University of Kansas and her BA in Chemistry at Colorado College.
Dr. Stevenson has authored over 90 peer reviewed publications,
presentations, and patents.
Jonathan R. Coppeta, PhD -- Vice President,
Engineering
Dr. Jonathan Coppeta is the Vice President of Engineering at
ODTx. Prior to ODTx, Dr. Coppeta spent nine years developing the
core technologies for long term Class III drug delivery and
biosensor implants at MicroCHIPS as the Director of Mechanical and
Materials Development. In this role, he invented key enabling
technologies including a room temperature hermetic sealing
technique compatible with sensitive drug formulations and sensor
chemistries and a novel amperometric sensor design for a long-term
implantable glucose sensor. He and his team were responsible for
many device development activities including MEMS design,
mechanical packaging, formulation filling, biocompatibility
testing, and materials selection and testing. Prior to MicroCHIPS,
Dr. Coppeta developed novel technologies in the optical
telecommunications field for Axsun Technologies. Several of his
patented inventions were transitioned into manufacturing of optical
subsystems currently deployed in the field. He is an inventor on 8
issued patents and 7 patent applications spanning the fields of
medical devices, biosensor design, hermetic sealing, and
microfabrication. Dr. Coppeta earned his PhD in Mechanical
Engineering from Tufts University and BS degree in Chemistry and
Physics from Bates College.
<<
Back to ODTx Leadership